Pfizer NDA submissions
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer is planning to submit an NDA for pregabalin in 2002 for add-on epilepsy, neuropathic pain and generalized anxiety disorder, the company says in a Dec. 18 analysts meeting. The firm had previously said it would file for epilepsy and pain in third quarter 2001. Other Pfizer filings expected in the next five years include: CP-526,555 for smoking cessation, pagoclone for anxiety, CP-122-721 for depression, darifenacin for overactive bladder, capravirine for AIDS and UK-338,003 for benign prostatic hyperplasia and erectile dysfunction
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.